Project Details
Description
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors
| Status | Active |
|---|---|
| Effective start/end date | 5/8/23 → 5/31/28 |
Funding
- BOEHRINGER-INGELHEIM PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.